Numerous investigations have shown that mitochondrial dysfunction is a major mechanism
of drug-induced liver injury, which involves the parent drug or a reactive metabolite …

Severe and prolonged impairment of mitochondrial β-oxidation leads to microvesicular
steatosis, and, in severe forms, to liver failure, coma and death. Impairment of mitochondrial …

Repurposing drugs as treatments for COVID-19, the disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning …

Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic
liver disease in the developing world, found in 17-30% of the population in Western …

A frequent mechanism for drug-induced liver injury (DILI) is the formation of reactive
metabolites that trigger hepatitis through direct toxicity or immune reactions. Both events …

The diagnosis of drug-induced liver injury (DILI) is a challenging problem, often confounded
by incomplete clinical information and the difficulty of eliciting exposure to herbal products …

Background & Aims: 4, 4'-Diethylaminoethoxyhexestrol (DEAEH), amiodarone, and
perhexiline cause steatohepatitis in humans. The mechanisms of these effects are unknown …

Drug-induced phospholipidosis is characterized by intracellular accumulation of
phospholipids with lamellar bodies, most likely from an impaired phospholipid metabolism of …

Amiodarone is an iodinated benzofuran derivative, a highly lipophilic drug with
unpredictable pharmacokinetics. Although originally classified as a class III agent due to its …

Microvesicular steatosis occurs in conditions characterized by severe impairment of the
mitochondrial β-oxidation process, due to genetic and/or acquired causes. Drugs and some …